Skip to main content

Articles

Page 4 of 38

  1. Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase with multiple roles in tumour growth, cell invasion and metastasis. We have previously established GSK-3 as an upstream regulator of PD-1 gene ex...

    Authors: Gary Shaw, Ludimila Cavalcante, Francis J. Giles and Alison Taylor
    Citation: Journal of Hematology & Oncology 2022 15:134
    Content type: Research Published on:

  2. Regulated cell death (RCD) is a critical and active process that is controlled by specific signal transduction pathways and can be regulated by genetic signals or drug interventions. Meanwhile, RCD is closely ...

    Authors: Rui Qin, Feng-Ming You, Qian Zhao, Xin Xie, Cheng Peng, Gu Zhan and Bo Han
    Citation: Journal of Hematology & Oncology 2022 15:133
    Content type: Review Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:151

  3. Poor targeting of therapeutics leading to severe adverse effects on normal tissues is considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug delivery systems have provided an ...

    Authors: Hailong Tian, Tingting Zhang, Siyuan Qin, Zhao Huang, Li Zhou, Jiayan Shi, Edouard C. Nice, Na Xie, Canhua Huang and Zhisen Shen
    Citation: Journal of Hematology & Oncology 2022 15:132
    Content type: Review Published on:

  4. Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), a...

    Authors: Mina Nikanjam, Shumei Kato and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2022 15:131
    Content type: Review Published on:

  7. circRNA has been established to play a pivotal role in tumorigenesis development in a variety of cancers; nevertheless, the biological functions and molecular mechanisms of hypoxia-induced exosomal circRNAs in...

    Authors: Jiewei Lin, Xinjing Wang, Shuyu Zhai, Minmin Shi, Chenghong Peng, Xiaxing Deng, Da Fu, Jiancheng Wang and Baiyong Shen
    Citation: Journal of Hematology & Oncology 2022 15:128
    Content type: Research Published on:

  8. Myeloid malignancies develop through the accumulation of genetic and epigenetic alterations that dysregulate hematopoietic stem cell (HSC) self-renewal, stimulate HSC proliferation and result in differentiatio...

    Authors: Edward A. Medina, Caroline R. Delma and Feng-Chun Yang
    Citation: Journal of Hematology & Oncology 2022 15:127
    Content type: Review Published on:

  9. The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutated IDH1/2 has not been defined. Therefore, we analyzed a large cohort of 3234 AML patients in first co...

    Authors: Desiree Kunadt, Sebastian Stasik, Klaus H. Metzeler, Christoph Röllig, Christoph Schliemann, Philipp A. Greif, Karsten Spiekermann, Maja Rothenberg-Thurley, Utz Krug, Jan Braess, Alwin Krämer, Andreas Hochhaus, Sebastian Scholl, Inken Hilgendorf, Tim H. Brümmendorf, Edgar Jost…
    Citation: Journal of Hematology & Oncology 2022 15:126
    Content type: Research Published on:

  10. Analysis of circulating free DNA (cfDNA) is a promising tool for personalized management of colorectal cancer (CRC) patients. Untargeted cfDNA analysis using whole-genome sequencing (WGS) does not need a prior...

    Authors: Ariane Hallermayr, Tobias Wohlfrom, Verena Steinke-Lange, Anna Benet-Pagès, Florentine Scharf, Ellen Heitzer, Ulrich Mansmann, Christopher Haberl, Maike de Wit, Holger Vogelsang, Markus Rentsch, Elke Holinski-Feder and Julia M. A. Pickl
    Citation: Journal of Hematology & Oncology 2022 15:125
    Content type: Research Published on:

  11. Myelodysplastic syndromes (MDS) are a heterogeneous clonal disease of myeloid neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and an increased risk of progression to acute ...

    Authors: Razan Mohty, Rama Al Hamed, Ali Bazarbachi, Eolia Brissot, Arnon Nagler, Amer Zeidan and Mohamad Mohty
    Citation: Journal of Hematology & Oncology 2022 15:124
    Content type: Review Published on:

  12. The vast majority of our knowledge regarding cancer radiobiology and the activation of radioresistance mechanisms emerged from studies using external beam radiation therapy (EBRT). Yet, less is known about the...

    Authors: Michal Grzmil, Paul Boersema, Ashish Sharma, Alain Blanc, Stefan Imobersteg, Martin Pruschy, Paola Picotti, Roger Schibli and Martin Behe
    Citation: Journal of Hematology & Oncology 2022 15:123
    Content type: Correspondence Published on:

  13. Circular RNAs (circRNAs) represent a novel type of regulatory RNA characterized by high evolutionary conservation and stability. CircRNAs are expected to be potential diagnostic biomarkers and therapeutic targ...

    Authors: Xiaolong Wang, Tong Chen, Chen Li, Wenhao Li, Xianyong Zhou, Yaming Li, Dan Luo, Ning Zhang, Bing Chen, Lijuan Wang, Wenjing Zhao, Shanji Fu and Qifeng Yang
    Citation: Journal of Hematology & Oncology 2022 15:122
    Content type: Research Published on:

  14. Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however...

    Authors: Yun Li, Huajun Zhang, Yulia Merkher, Lin Chen, Na Liu, Sergey Leonov and Yongheng Chen
    Citation: Journal of Hematology & Oncology 2022 15:121
    Content type: Review Published on:

  15. Metabolic reprogramming of cancer cells within the tumor microenvironment typically occurs in response to increased nutritional, translation and proliferative demands. Altered lipid metabolism is a marker of t...

    Authors: Yahui Zhu, Xingrong Lin, Xiaojun Zhou, Edward V. Prochownik, Fubing Wang and Youjun Li
    Citation: Journal of Hematology & Oncology 2022 15:120
    Content type: Review Published on:

  16. There is a paucity of information about molecularly driven therapy in osteosarcomas. We report a 31-year-old woman with chemotherapy–refractory metastatic osteosarcoma who was successfully treated with the com...

    Authors: Hanna E. Persha, Shumei Kato, Pradip De, Jacob J. Adashek, Jason K. Sicklick, Vivek Subbiah and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2022 15:119
    Content type: Correspondence Published on:

  17. Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolu...

    Authors: Yi Wang, Kai Conrad Cecil Johnson, Margaret E. Gatti-Mays and Zihai Li
    Citation: Journal of Hematology & Oncology 2022 15:118
    Content type: Review Published on:

  18. A cardinal feature that distinguishes clinically high-risk neuroblastoma from low-risk tumors is telomere maintenance. Specifically, neuroblastoma tumors with either active telomerase or alternative lengthenin...

    Authors: Eun Young Yu, Nai-Kong V. Cheung and Neal F. Lue
    Citation: Journal of Hematology & Oncology 2022 15:117
    Content type: Review Published on:

  19. Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disea...

    Authors: Darko Antic, Natasa Milic, Thomas Chatzikonstantinou, Lydia Scarfò, Vladimir Otasevic, Nina Rajovic, David Allsup, Alejandro Alonso Cabrero, Martin Andres, Monica Baile Gonzales, Antonella Capasso, Rosa Collado, Raul Cordoba, Carolina Cuéllar-García, Juan Gonzalo Correa, Lorenzo De Paoli…
    Citation: Journal of Hematology & Oncology 2022 15:116
    Content type: Research Published on:

  20. Patients with follicular lymphoma (FL) who experience disease progression within 24 months (POD24) have inferior outcomes. The tumor immune microenvironment (TIME) plays a crucial role in pathogenesis and prog...

    Authors: Long Liu, Xingxing Yu, Zhifeng Li, Xiaohua He, Jie Zha, Zhijuan Lin, Yan Hong, Huijian Zheng, Qian Lai, Kaiyang Ding, Xian Jia, Guo Fu, Haifeng Yu, Haiyan Yang, Zhiming Li, Ken H. Young…
    Citation: Journal of Hematology & Oncology 2022 15:115
    Content type: Correspondence Published on:

  21. Lung adenocarcinoma (LUAD) is the leading cause of death worldwide. However, the roles of long noncoding RNAs (lncRNAs) hijacked by super-enhancers (SEs), vital regulatory elements of the epigenome, remain elu...

    Authors: Te Zhang, Wenjie Xia, Xuming Song, Qixing Mao, Xing Huang, Bing Chen, Yingkuan Liang, Hui Wang, Yuzhong Chen, Xinnian Yu, Zeyu Zhang, Wenmin Yang, Lin Xu, Gaochao Dong and Feng Jiang
    Citation: Journal of Hematology & Oncology 2022 15:114
    Content type: Research Published on:

  22. BCR-ABL1T315I mutations confer resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Olverembatinib is a new potent BCR-ABL1 TKI with preclinical activity against T315I-mutated CML. I...

    Authors: Qian Jiang, Zongru Li, Yazhen Qin, Weiming Li, Na Xu, Bingcheng Liu, Yanli Zhang, Li Meng, Huanling Zhu, Xin Du, Suning Chen, Yang Liang, Yu Hu, Xiaoli Liu, Yongping Song, Lichuang Men…
    Citation: Journal of Hematology & Oncology 2022 15:113
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:13

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:159

  23. Although a substantial increase in the survival of patients with other cancers has been observed in recent decades, pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest diseases. No effective s...

    Authors: Zengyu Feng, Kexian Li, Kai Qin, Juyong Liang, Minmin Shi, Yang Ma, Shiwei Zhao, Huaiyu Liang, Dongni Han, Baiyong Shen, Chenghong Peng, Hao Chen and Lingxi Jiang
    Citation: Journal of Hematology & Oncology 2022 15:112
    Content type: Research Published on:

  24. The discovery of immune checkpoint inhibitors (ICIs) has now been universally acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of checkpoint molecules: anti-programmed c...

    Authors: Yuchen Wang, Hao Zhang, Chao Liu, Zeyu Wang, Wantao Wu, Nan Zhang, Longbo Zhang, Jason Hu, Peng Luo, Jian Zhang, Zaoqu Liu, Yun Peng, Zhixiong Liu, Lanhua Tang and Quan Cheng
    Citation: Journal of Hematology & Oncology 2022 15:111
    Content type: Review Published on:

  25. Emerging evidence indicates that the detection and clearance of cancer cells via phagocytosis induced by innate immune checkpoints play significant roles in tumor-mediated immune escape. The most well-describe...

    Authors: Wei Li, Fang Wang, Rongqun Guo, Zhilei Bian and Yongping Song
    Citation: Journal of Hematology & Oncology 2022 15:110
    Content type: Review Published on:

  26. Multiple Myeloma (MM) is a progressive plasma cell neoplasm characterized by heterogeneous clonal expansion. Despite promising response rates achieved with anti-BCMA CAR-T cell therapy, patients may still rela...

    Authors: Muhammad Elnaggar, Sarita Agte, Paula Restrepo, Meghana Ram, David Melnekoff, Christos Adamopoulos, Mark M. Stevens, Katerina Kappes, Violetta Leshchenko, Daniel Verina, Sundar Jagannath, Poulikos I. Poulikakos, Samir Parekh and Alessandro Laganà
    Citation: Journal of Hematology & Oncology 2022 15:109
    Content type: Case Report Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2023 16:52

  27. The pathophysiology of COVID-19-associated coagulopathy is complex and not fully understood. SARS-CoV-2 spike protein (SP) may activate platelets and interact with fibrin(ogen). We aimed to investigate whether...

    Authors: Manuela De Michele, Giulia d’Amati, Martina Leopizzi, Marta Iacobucci, Irene Berto, Svetlana Lorenzano, Laura Mazzuti, Ombretta Turriziani, Oscar G. Schiavo and Danilo Toni
    Citation: Journal of Hematology & Oncology 2022 15:108
    Content type: Correspondence Published on:

  28. Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by pathogenic TP53 variants. The condition represents one of the most relevant genetic causes of cancer in children and adults due to its freq...

    Authors: Judith Penkert, Farina J. Strüwe, Christina M. Dutzmann, Beate B. Doergeloh, Emilie Montellier, Claire Freycon, Myriam Keymling, Heinz-Peter Schlemmer, Birte Sänger, Beatrice Hoffmann, Tanja Gerasimov, Claudia Blattmann, Sebastian Fetscher, Michael Frühwald, Simone Hettmer, Uwe Kordes…
    Citation: Journal of Hematology & Oncology 2022 15:107
    Content type: Correspondence Published on:

  29. Multiple myeloma (MM) and its precursors monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) are 2–3 times more common in African Americans (AA) than European Americans (EA)....

    Authors: Brian C.-H. Chiu, Zhou Zhang, Benjamin A. Derman, Jason Karpus, Liangzhi Luo, Sheng Zhang, Spencer S. Langerman, Madina Sukhanova, Parveen Bhatti, Andrzej Jakubowiak, Chuan He and Wei Zhang
    Citation: Journal of Hematology & Oncology 2022 15:106
    Content type: Correspondence Published on:

  30. This study prospectively compared the efficacy and safety between matched related donor-hematopoietic stem cell transplantation (MRD-HSCT) (n = 108) and immunosuppressive therapy (IST) plus eltrombopag (EPAG) (IS...

    Authors: Limin Liu, Meiqing Lei, Rong Fu, Bing Han, Xin Zhao, Rongrong Liu, Yanming Zhang, Wenjing Jiao, Miao Miao, Fengkui Zhang, Liansheng Zhang and Depei Wu
    Citation: Journal of Hematology & Oncology 2022 15:105
    Content type: Correspondence Published on:

  31. Characterized by the expression of the critical transcription factor forkhead box protein P3, regulatory T (Treg) cells are an essential part of the immune system, with a dual effect on the pathogenesis of aut...

    Authors: Yuheng Yan, Lan Huang, Yiming Liu, Ming Yi, Qian Chu, Dechao Jiao and Kongming Wu
    Citation: Journal of Hematology & Oncology 2022 15:104
    Content type: Review Published on:

  32. Patients with higher-risk myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs) have limited therapeutic options and an expected overall survival (OS) of 3–5 months. Eltanexor is an inves...

    Authors: Sangmin Lee, Sanjay Mohan, Jessica Knupp, Kamal Chamoun, Adrienne de Jonge, Fan Yang, Erkan Baloglu, Jatin Shah, Michael G. Kauffman, Sharon Shacham and Bhavana Bhatnagar
    Citation: Journal of Hematology & Oncology 2022 15:103
    Content type: Correspondence Published on:

  34. Hemophagocytic lymphohistiocytosis (HLH), particularly primary HLH (pHLH), is a rare, life-threatening disease. Germline genetic deficiency of 12 known HLH genes impairs cytotoxic degranulation in natural kill...

    Authors: Xiaoman Bi, Qing Zhang, Lei Chen, Dan Liu, Yueying Li, Xiaoxi Zhao, Ya Zhang, Liping Zhang, Jingkun Liu, Chaoyi Wu, Zhigang Li, Yunze Zhao, Honghao Ma, Gang Huang, Xin Liu, Qian-fei Wang…
    Citation: Journal of Hematology & Oncology 2022 15:101
    Content type: Correspondence Published on:

  35. Authors: Yang Zhang, Xiaoyi Chen, Huamin Wang, Shanisha Gordon-Mitchell, Srabani Sahu, Tushar D. Bhagat, Gaurav Choudhary, Srinivas Aluri, Kith Pradhan, Plabani Sahu, Milagros Carbajal, Hui Zhang, Beamon Agarwal, Aditi Shastri, Robert Martell, Daniel Starczynowski…
    Citation: Journal of Hematology & Oncology 2022 15:100
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2022 15:70

  36. Both extracellular vesicles from mesenchymal stromal cell-derived human umbilical cords (hUC-EVs) and arsenic trioxides (ATOs) have been demonstrated to treat acute graft-versus-host disease (aGVHD) via immuno...

    Authors: Yan Su, Xueyan Sun, Xiao Liu, Qingyuan Qu, Liping Yang, Qi Chen, Fengqi Liu, Yueying Li, Qianfei Wang, Bo Huang, Xiao-Jun Huang and Xiao-Hui Zhang
    Citation: Journal of Hematology & Oncology 2022 15:99
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:102

  38. Drug resistance represents a major obstacle in cancer management, and the mechanisms underlying stress adaptation of cancer cells in response to therapy-induced hostile environment are largely unknown. As the ...

    Authors: Ping Jin, Jingwen Jiang, Li Zhou, Zhao Huang, Edouard C. Nice, Canhua Huang and Li Fu
    Citation: Journal of Hematology & Oncology 2022 15:97
    Content type: Review Published on:

  39. Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibru...

    Authors: Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Cherie Tan…
    Citation: Journal of Hematology & Oncology 2022 15:96
    Content type: Correspondence Published on:

  40. Chemotherapy combined with or without targeted therapy is the fundamental treatment for metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs and the biological characterist...

    Authors: Junyong Weng, Shanbao Li, Zhonglin Zhu, Qi Liu, Ruoxin Zhang, Yufei Yang and Xinxiang Li
    Citation: Journal of Hematology & Oncology 2022 15:95
    Content type: Review Published on:

  41. Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related to the inhibition of tum...

    Authors: Kunyu Shi, Guan Wang, Junping Pei, Jifa Zhang, Jiaxing Wang, Liang Ouyang, Yuxi Wang and Weimin Li
    Citation: Journal of Hematology & Oncology 2022 15:94
    Content type: Review Published on:

  42. Bladder cancer is the most common malignant tumor of the urinary system. Surgical resection and chemotherapy are the two mainstream treatments for bladder cancer. However, the outcomes are not satisfactory for...

    Authors: Wenlong Zhang, Xin He, Haoli Yin, Wenmin Cao, Tingsheng Lin, Wei Chen, Wenli Diao, Meng Ding, Hao Hu, Wenjing Mo, Qing Zhang and Hongqian Guo
    Citation: Journal of Hematology & Oncology 2022 15:93
    Content type: Research Published on:

  43. Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel se...

    Authors: Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Sujay Kalathoor, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Jennifer Woyach…
    Citation: Journal of Hematology & Oncology 2022 15:92
    Content type: Research Published on:

  44. p53, encoded by the tumor suppressor gene TP53, is one of the most important tumor suppressor factors in vivo and can be negatively regulated by MDM2 through p53–MDM2 negative feedback loop. Abnormal p53 can b...

    Authors: Haohao Zhu, Hui Gao, Yingying Ji, Qin Zhou, Zhiqiang Du, Lin Tian, Ying Jiang, Kun Yao and Zhenhe Zhou
    Citation: Journal of Hematology & Oncology 2022 15:91
    Content type: Review Published on:

  45. Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second- and third-generation TKIs were devel...

    Authors: Valentin García-Gutiérrez, Massimo Breccia, Elias Jabbour, Michael Mauro and Jorge E. Cortes
    Citation: Journal of Hematology & Oncology 2022 15:90
    Content type: Review Published on:

  46. Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis. Currently, VEGFR inhibitors ...

    Authors: Yun Liu, Yang Li, Yuxi Wang, Congcong Lin, Dan Zhang, Juncheng Chen, Liang Ouyang, Fengbo Wu, Jifa Zhang and Lei Chen
    Citation: Journal of Hematology & Oncology 2022 15:89
    Content type: Review Published on:

  47. Relapsed or refractory (R/R) acute myeloid leukemia (AML) has a poor prognosis. In this study, we evaluated chimeric antigen receptor (CAR) T cell therapy targeting CLL-1 in adults with R/R AML patients. Patie...

    Authors: Xin Jin, Meng Zhang, Rui Sun, Hairong Lyu, Xia Xiao, Xiaomei Zhang, Fan Li, Danni Xie, Xia Xiong, Jiaxi Wang, Wenyi Lu, Hongkai Zhang and Mingfeng Zhao
    Citation: Journal of Hematology & Oncology 2022 15:88
    Content type: Correspondence Published on:

  48. The development of combination immunotherapy based on the mediation of regulatory mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep understanding of tumor immunology must inv...

    Authors: Liangliang Xu, Chang Zou, Shanshan Zhang, Timothy Shun Man Chu, Yan Zhang, Weiwei Chen, Caining Zhao, Li Yang, Zhiyuan Xu, Shaowei Dong, Hao Yu, Bo Li, Xinyuan Guan, Yuzhu Hou and Feng-Ming Kong
    Citation: Journal of Hematology & Oncology 2022 15:87
    Content type: Review Published on:

  49. Metastasis and chemoresistance are major culprits of cancer mortality, but factors contributing to these processes are incompletely understood.

    Authors: Hsin-Yi Chen, Shu-Jou Chan, Xinxin Liu, An-Chi Wei, Ru-In Jian, Kuan-Wei Huang, Yaw-Dong Lang, Jou-Ho Shih, Chun-Chieh Liao, Chiu-Lin Luan, Yu-Tung Kao, Shang-Yin Chiang, Pei-Wen Hsiao, Yuh-Shan Jou, Yunching Chen and Ruey-Hwa Chen
    Citation: Journal of Hematology & Oncology 2022 15:85
    Content type: Research Published on:

  50. The tumor microenvironment (TME), which is regulated by intrinsic oncogenic mechanisms and epigenetic modifications, has become a research hotspot in recent years. Characteristic features of TME include hypoxi...

    Authors: Fusheng Zhang, Haiyang Liu, Meiqi Duan, Guang Wang, Zhenghou Zhang, Yutian Wang, Yiping Qian, Zhi Yang and Xiaofeng Jiang
    Citation: Journal of Hematology & Oncology 2022 15:84
    Content type: Review Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2022 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    74 days submission to accept (Median)

    2022 Usage 
    2,836,875 downloads
    9,883 Altmetric mentions 

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us